24 June 2019 - A controversial change of epilepsy drug funding could see her and thousands of other people with epilepsy lose their quality of life and livelihoods, Brighton massage therapist Jemima Pedro-Davison fears.
Government drug-buying agency PHARMAC recently opted to change its funding from a range of lamotrigine epilepsy medications to just a single brand, Logem.
About 45,000 New Zealanders have epilepsy, and their national organisation Epilepsy New Zealand is deeply concerned that proven effective drug Lamictal will no longer be funded.